var data={"title":"Methylphenidate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methylphenidate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6566?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methylphenidate-drug-information\" class=\"drug drug_general\">see &quot;Methylphenidate: Drug information&quot;</a> and <a href=\"topic.htm?path=methylphenidate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methylphenidate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709144\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Abuse and dependence:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">CNS stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Long-term abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use because severe depression may occur. Withdrawal following long-term therapeutic use may unmask symptoms of the underlying disorder that may require follow-up.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195295\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aptensio XR;</li>\n      <li>Concerta;</li>\n      <li>Cotempla XR-ODT;</li>\n      <li>Daytrana;</li>\n      <li>Metadate CD [DSC];</li>\n      <li>Metadate ER;</li>\n      <li>Methylin;</li>\n      <li>QuilliChew ER;</li>\n      <li>Quillivant XR;</li>\n      <li>Ritalin;</li>\n      <li>Ritalin LA;</li>\n      <li>Ritalin SR [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195296\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Biphentin;</li>\n      <li>Concerta;</li>\n      <li>Foquest;</li>\n      <li>Ritalin;</li>\n      <li>Ritalin SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053970\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Central Nervous System Stimulant</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053963\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=methylphenidate-drug-information\" class=\"drug drug_general\">see &quot;Methylphenidate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Discontinue medication if no improvement is seen after appropriate dosage adjustment over a 1-month period of time: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Attention-deficit/hyperactivity disorder: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Immediate release products (eg, Methylin, Ritalin):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 3 to 5 years, moderate to severe dysfunction: Limited data available;  AAP considers first-line agent in this patient population if pharmacological treatment deemed necessary (AAP 2011): Initial: 1.25 mg twice daily; titrate to effect at weekly intervals; usual reported daily range: 3.75 to 30 mg/day divided into two or three daily doses (Ghuman 2008; Greenhill 2006). In the largest trial, a multicenter, randomized, placebo-controlled, crossover study of 165 preschool children (age range: 3 to 5.5 years), statistically and clinically significant improvements in ADHD scores were reported with doses of 2.5 mg, 5 mg, and 7.5 mg 3 times daily; in some patients [n=7 (4%)], dose titration to 10 mg 3 times daily was necessary; the mean effective total daily dose: 14.2 &plusmn; 8.1 mg/<b>day</b>. Although ADHD scores were statistically and clinically improved with methylphenidate use, the effect size was smaller with this younger patient population than that seen in school-age children (Greenhill 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 years and Adolescents: Initial: 0.3 mg/kg/dose or 2.5 to 5 mg/dose given before breakfast and lunch; increase by 0.1 mg/kg/dose or by 5 to 10 mg/day at weekly intervals; usual dose: 0.3 to 1 mg/kg/day or 20-30 mg/<b>day</b> in 2 to 3 divided doses; maximum daily dose dependent upon patient weight: 2 mg/kg/day or if patient weight &le;50 kg: 60 mg/<b>day</b>; in patients &gt;50 kg: 100 mg/day (Dopheide 2009, Pliszka 2007); some patients may require 3 doses/day (ie, additional dose at 4 PM) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Extended release, sustained release and long acting products: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metadate ER, Ritalin-SR: Children &ge;6 years and Adolescents: Sustained release and extended release tablets (duration of action ~8 hours) may be given in place of regular tablets, once the daily dose is titrated using the immediate release products and the titrated 8-hour dosage corresponds to sustained/extended release tablet size; Ritalin SR&reg; may be administered once or twice daily (AAP 2011). Maximum daily dose is dependent upon patient weight: &le;50 kg: 60 mg/<b>day</b>;  &gt;50 kg: 100 mg/<b>day</b> (Dopheide 2009; Pliszka 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Concerta: Children &ge;6 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Methylphenidate-naive patients:</i> Initial: 18 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients currently using immediate release methylphenidate:</i> Initial dose: Dosing based on current regimen and clinical judgment; suggested dosing listed below: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Switching from methylphenidate immediate release 5 mg 2 to 3 times daily: Concerta 18 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Switching from methylphenidate immediate release 10 mg 2 to 3 times daily: Concerta 36 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Switching from methylphenidate immediate release 15 mg 2 to 3 times daily: Concerta 54 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Switching from methylphenidate immediate release 20 mg 2 to 3 times daily: Concerta 72 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Dosage adjustment:</i> May increase by Concerta 18 mg/day increments at weekly intervals. <b>Note:</b> A dosage strength of 27 mg is available for situations in which a dosage between 18 to 36 mg is desired.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Maximum daily dose of Concerta: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 6 to 12 years: 54 mg/day; for patients &gt;50 kg, higher maximum daily doses may be considered (108 mg/day) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&le;50 kg: 72 mg/day; not to exceed ~2 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;50 kg:108 mg/day (Dopheide 2009; Pliszka 2007)  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD: Children &ge;6 years and Adolescents: Initial: 20 mg once daily; may increase by 10 to 20 mg/day increments at weekly intervals; maximum daily dose dependent upon patient weight: &le;50 kg: 60 mg/<b>day</b>;  &gt;50 kg: 100 mg/<b>day</b> (Dopheide 2009; Pliszka 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Quillivant XR: Children 6 to 12 years: Initial: 20 mg once daily; may increase by 10 to 20 mg/day increments at weekly intervals; maximum daily dose: 60 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin LA: Children &ge;6 years and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Methylphenidate-naive patients:</i> Initial: 20 mg once daily; may increase by 10 mg/day increments at weekly intervals; maximum daily dose dependent upon patient weight: &le;50 kg: 60 mg/<b>day</b>; &gt;50 kg: 100 mg/<b>day</b> (Dopheide 2009; Pliszka 2007). <b>Note:</b> If a lower initial dose is desired, patients may begin with Ritalin LA 10 mg once daily. Alternatively, patients may begin therapy with an immediate release product, and switch to Ritalin LA once immediate release dosage is titrated to 5 mg twice daily (see below) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Patients currently receiving  immediate release methylphenidate:</i> Initial dose: Dosing based on current regimen and clinical judgment; use equivalent total daily dose administered once daily. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Patients currently receiving methylphenidate sustained release (SR):</i>  The same total daily dose of Ritalin LA should be used.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Dosage adjustment:</i> May increase Ritalin LA: by 10 mg/day increments at weekly intervals  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Maximum daily dose of Ritalin LA: Dependent upon patient weight: &le;50 kg: 60 mg/<b>day</b>; &gt;50 kg: 100 mg/<b>day</b> (Dopheide 2009; Pliszka 2007)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Transdermal patch (Daytrana): Children and Adolescents 6 to 17 years: Initial: 10 mg (12.5 cm<sup>2</sup>) patch once daily; apply to hip 2 hours before effect is needed and remove 9 hours after application; titrate dose based on response and tolerability; may increase to next transdermal patch dosage size no more frequently than every week. Patch may be removed before 9 hours if a shorter duration of action is required or if late day adverse effects appear. Plasma concentrations usually start to decline when the patch is removed but drug absorption may continue for several hours after patch removal. <b>Note:</b> The manufacturer&rsquo;s labeling recommends patients converting from another formulation of methylphenidate to the transdermal patch should be initiated at 10 mg regardless of their previous dose and titrated as needed due to the differences in bioavailability of the transdermal formulation. However, some clinicians have supported higher starting patch doses for patients converting from oral methylphenidate doses of &gt;20 mg/day; for example, the 15 mg (18.75 cm<sup>2</sup>) patch has been investigated to have the same effect as 22.5 mg daily of the immediate release preparation, 27 mg daily of the osmotic release preparation (Concerta), or 20 mg daily of the encapsulated bead preparation (Metadate CD) (Arnold 2007). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Narcolepsy:</b> Children &ge;6 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release tablets and oral solution (Methylin, Ritalin): Initial: 5 mg twice daily given before breakfast and lunch; increase by 5 to 10 increments mg/day at weekly intervals; 2 to 3 times per day; maximum daily dose: 60 mg/<b>day</b> (in 2 to 3 divided doses)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Extended/sustained release tablets (Metadate ER, Ritalin-SR): May be given in place of immediate release products (duration of action: ~8 hours), once the immediate release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum daily dose: 60 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Attention-deficit/hyperactivity disorder:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release (IR) products (tablets, chewable tablets, and solution): Initial: 5 mg twice daily, before breakfast and lunch; increase by 5 to 10 mg daily at weekly intervals; maximum dose: 60 mg daily (in 2 to 3 divided doses)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (ER), sustained release (SR) products (capsules, tablets, and oral suspension):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Concerta: Adults &lt;65 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients not currently taking methylphenidate: Initial dose: 18 to 36 mg once every morning </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients currently taking methylphenidate: <b>Note:</b> Initial dose: Dosing based on current regimen and clinical judgment; suggested dosing listed below: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Switching from methylphenidate 5 mg 2 to 3 times daily: 18 mg once every morning </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Switching from methylphenidate 10 mg 2 to 3 times daily: 36 mg once every morning </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Switching from methylphenidate 15 mg 2 to 3 times daily: 54 mg once every morning </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Switching from methylphenidate 20 mg 2 to 3 times daily: 72 mg once every morning </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dose adjustment: May increase dose in increments of 18 mg; dose may be adjusted at weekly intervals. A dosage strength of 27 mg is available for situations in which a dosage between 18 to 36 mg is desired; maximum dose: 72 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Metadate ER, Ritalin-SR: May be given in place of immediate release products, once the daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum: 60 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Metadate CD, Quillivant XR : Initial: 20 mg once daily; may be adjusted in 10 to 20 mg increments at weekly intervals; maximum: 60 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ritalin LA: Initial: 20 mg once daily (10 mg once daily may be considered for some patients); may be adjusted in 10 mg increments at weekly intervals; maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from immediate release or sustained release methylphenidate formulation to Ritalin LA: Use equivalent total daily dose administered once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Narcolepsy:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release tablets and solution (Methylin, Ritalin): Initial: 5 mg twice daily before breakfast and lunch; increase by 5 to 10 mg daily at weekly intervals; 10 mg 2 to 3 times per day; maximum daily dose: 60 mg/day (in 2 to 3 divided doses).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended/sustained release tablets (Metadate ER, Ritalin-SR): May be given in place of immediate release products (duration of action: ~8 hours), once the immediate release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment for renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: There are no dosage adjustments provided in manufacturer's labeling (has not been studied); undergoes extensive metabolism to a renally eliminated metabolite with little or no pharmacologic activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling (has not been studied).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195272\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD: 10 mg [DSC], 20 mg [DSC], 30 mg [DSC] [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD: 40 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD: 50 mg [DSC] [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD: 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 10 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 15 mg [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 20 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 30 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 40 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 50 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin LA: 10 mg, 20 mg, 30 mg, 40 mg, 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 30 mg, 40 mg, 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Daytrana: 10 mg/9 hr (30 ea); 15 mg/9 hr (30 ea); 20 mg/9 hr (30 ea); 30 mg/9 hr (30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Methylin: 5 mg/5 mL (500 mL); 10 mg/5 mL (500 mL) [contains polyethylene glycol; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (500 mL); 10 mg/5 mL (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Quillivant XR: 25 mg/5 mL (60 mL, 120 mL, 150 mL, 180 mL) [contains sodium benzoate; banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin: 10 mg, 20 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Methylin: 2.5 mg [DSC], 5 mg [DSC] [contains aspartame; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Methylin: 10 mg [DSC] [scored; contains aspartame; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable Extended Release, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">QuilliChew ER: 20 mg, 30 mg, 40 mg [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Concerta: 18 mg, 27 mg, 36 mg, 54 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate ER: 20 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate ER: 20 mg [additive free, color free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin SR: 20 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 18 mg, 20 mg, 27 mg, 36 mg, 54 mg, 72 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 18 mg, 27 mg, 36 mg, 54 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cotempla XR-ODT: 8.6 mg, 17.3 mg, 25.9 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195256\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50474161\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=methylphenidate-drug-information\" class=\"drug drug_general\">see &quot;Methylphenidate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aptensio XR capsules contain multi layered beads. The immediate release layer delivers approximately 40% of the methylphenidate dose, and the controlled release layer delivers approximately 60% of the methylphenidate dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concerta is an osmotic controlled release formulation (OROS) of methylphenidate. The tablet has an immediate-release overcoat providing an initial dose of methylphenidate within 1 hour, and the remaining is released at a controlled rate over 5-9 hours. The overcoat covers a trilayer core. The trilayer core is composed of two layers containing the drug and excipients, and one layer of osmotic components. As water from the gastrointestinal tract enters the core, the osmotic components expand and methylphenidate is released.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metadate CD capsules contain a mixture of immediate release and extended release beads, designed to release 30% of the dose immediately and 70% over an extended period.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritalin LA uses Spheroidal Oral Drug Absorption System (SODAS) design to deliver a bimodal release of medication, intended to mimic twice-daily administration of immediate-release methylphenidate. Fifty percent of the drug is delivered in immediate-release beads, and the remaining half is delivered in delayed-release beads approximately 4 hours after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195330\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874704\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Concerta: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf&amp;token=Z3+5wLFH3tbNKqerxb4rrYGgnvPKRaIZnQH7WzBjgt4YhDV2GaSAQFq1gmZYkbziN11EmR5LzJ//gVAClSc+/PfF7W1uhP9MMaem3oVOadU=&amp;TOPIC_ID=12600\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cotempla XR-ODT: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205489s000lbl.pdf#page=21&amp;token=hfBmR9RBX+ETlSnjOLqpNufD+9B1oBEyX47XfFIbEjoUPmLdATz/IBQYGzIxkv0qcMfOOCS0C4SJ4Bavpt6PleDDOCsL09JCZ0oZmHGxiOfzAev3ihmt6fuYphScy1TH&amp;TOPIC_ID=12600\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205489s000lbl.pdf#page=21</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Daytrana: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021514s025lbl.pdf#page=25&amp;token=MG6Knd8P0QaiY2u1/YPtvSAnaSm8kaA06PpiNE83OZ74NQFxjYstit4gdCjFPT3E1ZDsUyoVqHRINNlUA93bvhZLexc9T2MUcxEOL1oMEhYBIeMfXenGCV7ahyFf4xU8&amp;TOPIC_ID=12600\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021514s025lbl.pdf#page=25</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metadate CD: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021259s030lbl.pdf#page=20&amp;token=eSWHIQ4h88SNHJaQVikS9+AiCTVS4TC06dG1sqybMLxDu6czA7/FbeyP08X1CpRoNpP/logApLwh2jIxSgPOJDT2m5QSNAdvrIcId4/DHxUqFR8npJnHXN7DeDfPEanx&amp;TOPIC_ID=12600\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021259s030lbl.pdf#page=20</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methylin chewable tablet: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021475s010lbl.pdf#page=13&amp;token=Glgv7mddSmgjPHmmhX1L6XudUZP6Bycwt/9HtKXnTrYXNW5PcHnBMNwCy+3TE1kE/fRc9t6B6Ww8jJUrB8Jdw7YddV4xVcJ7H5qTcFzgvyAhmQmV/uYtDbkJ2e8jxNsM&amp;TOPIC_ID=12600\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021475s010lbl.pdf#page=13</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methylin immediate release oral solution: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021419s014lbl.pdf#page=12&amp;token=FdDYWusbnfzmikemm7imI1r8YckdMZevYb1sv1UmgwSKXEl2NaHx689KjNg3ffM6Ng8hbIyMzsKAttwICitHt1/RxiOUFwtPQsokBWE+lBlHdhKIFu17i+F2SzzCbI4/&amp;TOPIC_ID=12600\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021419s014lbl.pdf#page=12</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">QuilliChew ER: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207960s005lbl.pdf&amp;token=Ligr2U1U0E/RHuVGJJwk5B5txY7igO7FVl/k+zovh5obcLDHSZy4D8xsuZvhHIyQ2nuJJNI2ReOp7a/nCaO1jv4bhHulNyWVvZCkJ9gMERQ=&amp;TOPIC_ID=12600\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207960s005lbl.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Quillivant XR extended release oral suspension: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202100s012lbl.pdf#page=14&amp;token=sgue1VRxbi89Ggz7GyoGb0MijJLZRShfWEDLShT0Aaro3KEFPpYPjRfuLenD9FYaipXqrMxChtVeECes83gv8m/lrBINKl/TM/fclBrI2tqS8JOgyGMVd0pwg9iWfArC&amp;TOPIC_ID=12600\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202100s012lbl.pdf#page=14</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ritalin: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010187s087lbl.pdf#page=11&amp;token=7snEsWqzWWJm1cmXrT9zJgZi2suvoP9f5bnJSU0sqF3IH8tIvgnewKpx4nCaaiObA1EpQ3O3saJXorMy+dmmXqo4tsgfnyy/bLC/C5a8ARkFuwmYakeYByUTf3vsDplS&amp;TOPIC_ID=12600\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010187s087lbl.pdf#page=11</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ritalin LA: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021284s034lbl.pdf#page=18&amp;token=PCHEU0as/LkGByUitDbhqIxUjegyZrtf+PiDNxDUj2jaOGqlT7sHW+8wFX9pI0cQ7pQzZfZlHJl6drYLILgXENcGM5WsB7woLecG65gL37SfJWaOKrbYyn1DE2fIwEra&amp;TOPIC_ID=12600\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021284s034lbl.pdf#page=18</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ritalin-SR: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018029s055lbl.pdf#page=14&amp;token=OgXmtwamnc1jOK0lgfAVTnlrfmQwLVB+kX1/f8y9/uKtc6C6uw2lQlgoBj03xQ7hsl37ssI/sC+O9AeyV6O+fkIp52AcrpEeybTXwFa+TNpsKb2kenu3p1tXWg9hRb+n&amp;TOPIC_ID=12600\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018029s055lbl.pdf#page=14</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053974\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: To avoid insomnia, last daily dose should be administered several hours before retiring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release formulations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tablet (Ritalin), oral solution (Methylin): Administer on an empty stomach ~30 to 45 minutes before meals. Ensure last daily dose is administered before 6 PM if difficulty sleeping occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Chewable tablet (Methylin): Administer on an empty stomach ~30 to 45 minutes before meals with at least 8 ounces of water or other fluid; choking may occur if not enough fluids are taken. Ensure last daily dose is administered before 6 PM if difficulty sleeping occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended/sustained release formulations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Metadate ER:  May be taken with or without food. Swallow whole; do not crush, chew, or break tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Ritalin SR:  Administer 30 to 45 minutes before a meal. Swallow whole; do not crush, chew, or break tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Concerta: May be administered without regard to food, but must be taken with water, milk, or juice; administer dose once daily in the morning; do not crush, chew, or divide tablets </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Capsules:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Metadate CD: Administer dose once daily in the morning, before breakfast, with water, milk, or juice; capsule may be swallowed whole or opened and contents sprinkled on a small amount (one tablespoonful) of applesauce; immediately consume drug/applesauce mixture; do not store for future use; swallow applesauce without chewing; do not crush or chew capsule contents; drink fluids after consuming drug/applesauce mixture to ensure complete swallowing of beads; do not crush, chew, or divide capsules or its contents</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Ritalin LA: Administer dose once daily in the morning; may be administered with or without food (but some food may delay absorption); capsule may be swallowed whole or may be opened and contents sprinkled on a small amount (one spoonful) of applesauce. <b>Note:</b> Applesauce should not be warm; immediately consume drug/applesauce mixture; do not store for future use; do not crush, chew, or divide capsule or its contents.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Powder for oral suspension (Quillivant XR): Administer in the morning with or without food. Shake bottle &ge;10 seconds prior to administration. Use the oral dosing dispenser provided; wash after each use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Topical: Transdermal (Daytrana): Apply patch immediately after opening pouch and removing protective liner; do not use patch if pouch seal is broken; do not cut patch; do not use patches that are cut or damaged. If difficulty is experienced when separating the patch from the liner or if any medication (sticky substance) remains on the liner after separation, discard that patch and apply a new patch. Apply to clean, dry, healthy skin on the hip; do not apply to oily, damaged, or irritated skin; do not apply to the waistline; do not premedicate the patch site with hydrocortisone or other solutions, creams, ointments, or emollients. Apply at the same time each day, 2 hours before effect is needed. Alternate site of application daily (ie, use alternate hip). Press patch firmly for 30 seconds to ensure proper adherence. Remove patch 9 hours after application. Patch may be removed earlier if a shorter duration of action is required or if late day adverse effects occur. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Avoid exposure of application site to external heat source (eg, hair dryers, electric blankets, heating pads, heated water beds), which may significantly increase the rate and amount of drug absorbed. Exposure of patch to water during swimming, bathing, or showering may affect patch adherence. Do not reapply patch with dressings, tape, or other adhesives. If patch should become dislodged, may replace with new patch (to different site) but total wear time should not exceed 9 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">During removal, peel off patch slowly. If needed, patch removal may be helped by applying an oil-based product (ie, mineral oil, olive oil, or petroleum jelly) to the patch edges, gently working it underneath the patch edges. If a patch is not able to be removed, contact a physician or pharmacist. Nonmedical adhesive removers and acetone-based products, such as nail polish remover, should not be used to remove patches or adhesive. If adhesive residue remains on child's skin after patch removal, use an oil-based product and gently rub area to remove adhesive. Avoid touching the sticky side of the patch. Wash hands with soap and water after handling. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dispose of used patch by folding adhesive side onto itself, and discard in toilet or appropriate lidded container; discard unused patches that are no longer needed in the same manner; protective pouch and liner should be discarded in an appropriate lidded container. <b>Note:</b> Used patches contain residual drug; keep all transdermal patches out of the reach of children.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195291\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Capsule: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Aptensio XR:</i> Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Metadate CD, Ritalin LA:</i> Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Controlled-release (Biphentin, Foquest [Canadian products]):</i> Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture. After sprinkling Foquest on food, the mixture should be used immediately or within 10 minutes of mixing; discard if greater than 10 minutes after mixing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Solution: </b>\n      <i>Immediate-release (Methylin):</i> Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Suspension: </b> <i>Extended-release (Quillivant XR):</i> Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F), before and after reconstitution. Reconstituted bottle must be used within 4 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tablet:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate-release chewable (Methylin): </i> Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Metadate ER:</i> Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Concerta:</i> Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from humidity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-release chewable (QuilliChew ER):</i> Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release orally disintegrating (Cotempla XR-ODT): </i>Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store in reusable travel case.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate-release (Ritalin): </i> Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sustained-release (Ritalin-SR):</i> Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transdermal system: </b> <i>Daytrana:</i> Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Keep patches stored in protective pouch. Once tray is opened, use patches within 2 months; once an individual patch has been removed from the pouch and the protective liner removed, use immediately. Do not refrigerate or freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053973\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Concerta&reg;: Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages 6-65 years)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ritalin LA&reg;, Quillivant&trade; XR: Treatment of ADHD (FDA approved in ages 6-12 years)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metadate CD&reg;: Treatment of ADHD (FDA approved in ages 6-15 years)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metadate&reg; ER, Methylin&reg;, Ritalin&reg;, Ritalin SR&reg;: Treatment of ADHD, treatment of narcolepsy (All indications: FDA approved in ages &ge;6 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical Patch: Daytrana&reg;: Treatment of ADHD (FDA approved in ages 6-17 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195336\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD may be confused with Metadate ER</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate ER may be confused with methadone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Methylphenidate may be confused with methadone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">QuilliChew ER may be confused with Quillivant XR</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin may be confused with Rifadin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin LA may be confused with Ritalin-SR</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195334\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, decreased blood pressure, decreased pulse, heart murmur, hypertension, increased pulse, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation (oral), aggressive behavior (oral), anxiety (oral), confusion (oral), depressed mood (oral), depression, dizziness, emotional lability, Gilles de la Tourette syndrome (rare), headache, hypertonia (oral), hypervigilance, insomnia (including initial insomnia), irritability, jitteriness, lack of emotion (oral), mood changes, nervousness, outbursts of anger, panic attack, paresthesia, psychomotor agitation, restlessness (oral), sedation (oral), sleep disorder, tension (oral), tension headache (oral), tics (more common in transdermal), toxic psychosis, vertigo (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Excoriation (oral), hyperhidrosis (oral), macular eruption, skin rash (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido (oral), growth suppression, hot flash, increased thirst, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, abdominal pain (transdermal), anorexia, bruxism (oral), constipation (oral), decreased appetite, diarrhea, dyspepsia (oral), motion sickness (oral), nausea, upper abdominal pain (oral), vomiting (more common in transdermal), xerostomia (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Erectile dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Muscle spasm, tremor (oral), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, dry eye syndrome, eye pain (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (oral), dyspnea, nasopharyngitis (oral), oropharyngeal pain (oral), sinusitis, upper respiratory tract infection (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Accommodation disturbance, allergic contact dermatitis, allergic contact sensitivity, alopecia, angina pectoris, application site reaction, arthralgia, auditory hallucination, bradycardia, cerebral arteritis, cerebrovascular occlusion, change in libido, change in WBC count, chest discomfort, chest pain, decreased platelet count, decreased therapeutic response, diplopia, disorientation, drowsiness, dyskinesia, erythema, extrasystoles, fatigue, hallucination, hepatic failure (acute), hepatic injury (severe), hyperpyrexia, hypersensitivity reaction (including angioedema, anaphylaxis, auricular swelling, bullous conditions, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, pruritus), immune thrombocytopenia, increased blood pressure, increased heart rate, increased liver enzymes, increased serum alkaline phosphatase, increased serum bilirubin, lethargy, leukoderma (chemical; FDA Safety Alert 2015), loss of scalp hair, mania, muscle twitching, myalgia, mydriasis, neuroleptic malignant syndrome, pancytopenia, peripheral vascular insufficiency, priapism, Raynaud phenomenon, rhabdomyolysis, seizure, supraventricular tachycardia, talkativeness, thrombocytopenia, thrombotic thrombocytopenic purpura, tonic-clonic seizures, urticaria, ventricular premature contractions, visual disturbance, visual hallucination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195278\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Hypersensitivity (eg, angioedema, anaphylaxis) to methylphenidate or any component of the formulation; use during or within 14 days following MAO inhibitor therapy; marked anxiety, tension, and agitation (excluding Aptensio XR, Cotempla XR-ODT, QuilliChew ER, and Quillivant XR); glaucoma (excluding Aptensio XR, Cotempla XR-ODT, QuilliChew ER, and Quillivant XR); family history or diagnosis of Tourette syndrome or tics (excluding Aptensio XR, Cotempla XR-ODT, QuilliChew ER, and Quillivant XR)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Additional contraindications: Metadate CD: Severe hypertension, heart failure, arrhythmia, hyperthyroidism or thyrotoxicosis, recent MI or angina; concomitant use of halogenated anesthetics; patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltase insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to methylphenidate or any component of the formulation; marked anxiety, tension, and agitation; glaucoma; use during or within 14 days following MAO inhibitor therapy; family history or diagnosis of Tourette syndrome or tics (excluding Concerta), thyrotoxicosis, advanced arteriosclerosis, symptomatic cardiovascular disease, or moderate to severe hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Additional contraindications:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foquest: Known hypersensitivity or idiosyncrasy to sympathomimetic amines; history of drug abuse</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ritalin and Ritalin SR: Pheochromocytoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195260\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: CNS stimulant use has been associated with serious cardiovascular events (eg, sudden death, arrhythmia, and myocardial infarction in children and adolescents; sudden death, stroke, and myocardial infarction in adults) in patients with and without preexisting structural cardiac abnormalities or other serious heart problems (Shin 2016). These products should be avoided in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could further increase their risk of sudden death. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. Some products are contraindicated in patients with heart failure, arrhythmias or recent MI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chemical leukoderma: Transdermal system may cause a persistent loss of skin pigmentation at and around the application site, as well as at distant sites from the application site; loss of skin pigmentation may continue after discontinuation of transdermal system. May resemble vitiligo especially if loss of skin pigmentation occurs at areas distant from application site; use with caution in patients with a history and/or family history of vitiligo. Monitor for signs of skin depigmentation; immediately discontinue use if patient experiences chemical leukoderma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, such as angioedema and anaphylactic reactions have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs/symptoms are usually mild and intermittent, and generally improve with dose reduction or discontinuation. Digital ulceration and/or soft tissue breakdown have been observed rarely; monitor for digital changes during therapy and seek further evaluation (eg, rheumatology) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Prolonged and painful erections (priapism), sometimes requiring surgical intervention, have been reported (rarely) with methylphenidate and atomoxetine use in pediatric and adult patients. Priapism has been reported to develop after some time on the drug, often subsequent to an increase in dose but also during a period of drug withdrawal (drug holidays or discontinuation). Patients with certain hematological dyscrasias (eg, sickle cell disease), malignancies, perineal trauma, or concomitant use of alcohol, illicit drugs, or other medications associated with priapism may be at increased risk. Patients who develop abnormally sustained or frequent and painful erections should discontinue therapy and seek immediate medical attention. An emergent urological consultation should be obtained in severe cases. Priapism has been associated with different dosage forms and products; it is not known if rechallenge with a different formulation will risk recurrence. Avoidance of stimulants and atomoxetine may be preferred in patients with severe cases that were slow to resolve and/or required detumescence (Eiland 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual disturbance: Difficulty in accommodation and blurred vision have been reported with the use of stimulants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse potential: <b>[US Boxed Warning]: CNS </b><b>stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy. Long-term abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use because severe depression may occur. Withdrawal following long-term therapeutic use may unmask symptoms of the underlying disorder that may require follow-up. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disorders: Use with caution in patients with hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate. Some products are contraindicated in patients with severe hypertension, hyperthyroidism or angina.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Use with caution in patients with pre-existing psychosis or bipolar disorder (may induce mixed/manic episode). May exacerbate symptoms of behavior and thought disorder in psychotic patients; new-onset psychosis or mania may occur with stimulant use. Patients should be screened for bipolar disorder prior to treatment; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, mania) occur. May be associated with aggressive behavior or hostility (causal relationship not established); monitor for development or worsening of these behaviors. Suicidal ideation, attempts, and very rarely, completed suicide have been reported. Monitor for suicide-related behavior.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation; use is contraindicated with some products (AACAP [Murphy 2013; Pliszka 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Appetite suppression may occur, particularly in children. Use of stimulants has been associated with weight loss and slowing of growth rate; monitor growth rate and weight during treatment. Treatment interruption may be necessary in patients who are not increasing in height or gaining weight as expected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biphentin, Foquest [Canadian products]: Controlled-release capsules are not interchangeable with other controlled-release formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concerta: Should not be used with preexisting severe gastrointestinal narrowing conditions, such as esophageal motility disorders, small bowel disease, &ldquo;short&rdquo; gut syndrome, cystic fibrosis, history of peritonitis, chronic intestinal pseudo-obstruction, or Meckel diverticulum.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Daytrana: Transdermal system may cause allergic contact sensitization, characterized by intense local reactions (eg, edema, papules) that may spread beyond the patch site; sensitization may subsequently manifest systemically with other routes of methylphenidate administration; monitor closely. Avoid exposure of application site to any direct external heat sources (eg, hair dryers, heating pads, electric blankets); may increase the rate and extent of absorption and risk of overdose. Efficacy of therapy for &gt;7 weeks has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose/sucrose: Some dosage forms may contain lactose or sucrose; use with caution in patients intolerant to either component (some manufacturer labels recommend avoiding use in such patients).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Metadate CD: Concomitant use with halogenated anesthetics is contraindicated; may cause sudden elevations in blood pressure; if surgery is planned, do not administer Metadate CD on the day of surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylketonuria: Some dosage forms contain phenylalanine, which can be harmful to patients with phenylketonuria (PKU). Before prescribing, consider the combined daily amount of phenylalanine from all sources.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26017179\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Serious  cardiovascular events, including sudden death, may occur in patients with preexisting structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of CNS stimulants in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the sympathomimetic effects of a stimulant drug. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy.   If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as methylphenidate, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered. <b>Note:</b> ECG abnormalities and four cases of sudden cardiac death have been reported in children receiving clonidine with methylphenidate; reduce dose of methylphenidate by 40% when used concurrently with clonidine; consider ECG monitoring. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould 2009). In a large retrospective cohort study involving 1,200,438 children and young adults (age: 2 to 24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31 to 1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57 to 1.89) users compared to nonusers. It should be noted that due to the upper limit of the 95% CI, the study could not rule out a doubling of the risk, albeit low (Cooper 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Stimulant medications may increase blood pressure (average increase 2 to 4 mm Hg) and heart rate (average increase 3 to 6 bpm). Long-term effects in pediatric patients have not been determined. Use of stimulants in children has been associated with growth suppression (monitor growth; treatment interruption may be needed). Appetite suppression may occur; monitor weight during therapy, particularly in children.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Evaluation of the effect of stimulants on growth in ADHD diagnosed children &lt;12 years receiving treatment for at least 3 years with stimulants has shown decreased height and weight changes over time compared to age matched control; height: 4.7 to 5.5 cm/year compared to 6.3 cm/year and 2.1 to 3.3 kg/year compared to 4.4 kg/year (Poulton 2016). In pediatric patients 8 to 17 years actively treated with stimulants, significant reductions in total femoral, femoral neck, and lumbar bone mineral density (BMD) were observed compared to matched unmedicated cohorts; also reported were significantly more subjects in the stimulant-treated group with BMD measurements in the osteopenic range compared to matched cohorts (38.3% to 21.6%) (Howard 2015). A longitudinal cohort-controlled trial reported no difference in peak height velocity and final adult height in subjects with ADHD and/or treated with stimulants (Harstad 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use with caution in preschool-age children; clinical trials have shown children 3 to 5 years of age are more sensitive to methylphenidate adverse effects resulting in a greater discontinuation of therapy compared to school-age children (discontinuation rate from trials: 11% vs &lt;1 %) (Wigal 2006). The moderate to severe adverse effect profiles in children are age-related; in preschool children, the most commonly reported adverse effects were crabbiness/irritability, emotional outbursts, difficulty falling asleep, repetitive behavior/thoughts, and decreased appetite; in school-age children, they were decreased appetite, delay of sleep onset, headache, and stomach ache (Wigal 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195323\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195265\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12600&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Methylphenidate. Alcohol (Ethyl) may increase the serum concentration of Methylphenidate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihypertensive Agents: Methylphenidate may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Methylphenidate may enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: May enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloNIDine: Methylphenidate may enhance the adverse/toxic effect of CloNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Methylphenidate may increase the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: Methylphenidate may enhance the hypertensive effect of Inhalational Anesthetics. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Methylphenidate may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Methylphenidate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Methylphenidate may increase the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Methylphenidate may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Methylphenidate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Methylphenidate may increase the serum concentration of Primidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Methylphenidate may enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Methylphenidate may enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Methylphenidate may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195292\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethanol: Alcohol consumption increases the rate of methylphenidate release from Metadate CD (extended-release capsules), Ritalin LA (extended-release capsules), and QuilliChew ER (extended-release chewable tablet), but not from Concerta (extended-release tablet); an <i>in vitro</i> study involving Metadate CD and Ritalin LA showed that an alcohol concentration of 40% resulted in 84% and 98% of the methylphenidate being released in the first hour, respectively; a study involving QuilliChew ER showed that an alcohol concentration of 40% resulted in 90% of the methylphenidate being released in the first hour. Management: Avoid consuming alcohol during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: Food may increase oral absorption of immediate-release tablet/solution/chewable tablet. Management: Administer 30 to 45 minutes before meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195267\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195281\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Information related to the use of methylphenidate in pregnant women with attention-deficit/hyperactivity disorder (Bolea-Alamanac 2014; Dideriksen 2013) or narcolepsy (Maurovich-Horvat 2013; Thorpy 2013) is limited. If treatment of ADHD in pregnancy is needed, methylphenidate may be considered (Larsen 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053969\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Evaluate patients for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor CBC with differential, platelet count, liver enzymes, blood pressure, heart rate, height, weight, appetite, abnormal movements, growth in children. Patients should be re-evaluated at appropriate intervals to assess continued need of the medication. Observe for signs/symptoms of aggression or hostility, depression, delusional thinking, hallucinations, or mania. Monitor for visual disturbances. Monitor for signs of misuse, abuse, and addiction.   </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal system: Also monitor the application site for local adverse reactions and allergic contact sensitization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195259\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Mild CNS stimulant; blocks the reuptake of norepinephrine and dopamine into presynaptic neurons; appears to stimulate the cerebral cortex and subcortical structures similar to amphetamines </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195277\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action (AAP 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate-release formulations (chewable tablet, oral solution, tablet [Methylin, Ritalin]): 20 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended-release formulations (capsule [Metadate CD, Ritalin LA], tablets [Concerta]): 20 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sustained-release tablet (Ritalin-SR): 60 to 180 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal (Daytrana): 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Oral: Controlled-release: Foquest [Canadian product]: Within 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: Oral: Immediate-release tablet: Within 2 hours; Sustained-release tablet: Within 4 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release formulations (chewable tablet, oral solution, immediate-release tablet [Methylin, Ritalin]): 3 to 5 hours (AAP 2011; Jain 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release capsule: Metadate CD, Ritalin LA: 6 to 8 hours (AAP 2011); Aptensio XR: &le;16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release tablet (Concerta): 8 to 12 hours (AAP 2011; Jain 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sustained-release tablet (Ritalin-SR): 2 to 8 hours (AAP 2011; Jain 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Controlled-release capsule (Foquest [Canadian product]): 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal (Daytrana): 11 to 12 hours (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Readily absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release chewable tablet: Methylin: A high-fat meal delayed peak time (~1 hour) and increased AUC (~20%).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Controlled-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Biphentin [Canadian product]: Food delayed initial peak slightly (~18 minutes); relative to immediate-release tablets, AUC is similar in fed or fasted state (~100%)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Foquest [Canadian product]: Food does not significantly affect AUC and C<sub>max</sub></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aptensio XR: A high-fat meal increased C<sub>max</sub> (~28%) and AUC (~19%). At an alcohol concentration up to 40% there was 96% release of methylphenidate within 2 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Metadate CD: A high-fat meal delayed the early peak (~1 hour), and increased C<sub>max</sub> (~30%) and AUC (~17%). At an alcohol concentration of 40%, there was an increase in the release rate of methylphenidate in the first hour, resulting in 84% of the methylphenidate being released.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Ritalin LA: A high-fat meal delayed absorption and peak times, but not the amount absorbed nor initial peak concentration (second peak lowered by ~25%). At an alcohol concentration of 40%, there was a 98% release of methylphenidate in the first hour.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release chewable tablet: A high-fat meal increased C<sub>max</sub> (~20%) and AUC<sub>inf</sub> (~4%). At an alcohol concentration of 40%, there was an increase in the release rate of methylphenidate in the first hour, resulting in 90% of the methylphenidate being released.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release orally disintegrating tablet: Cotempla XR-ODT: A high-fat meal decreased C<sub>max</sub> (24%) and increased AUC<sub>inf </sub>(16%) and led to an earlier peak (~0.5 hour).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release suspension: Quillivant XR: A high-fat meal led to an earlier peak (~1 hour), and increased C<sub>max</sub> (~28%) and AUC (~19%).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release tablet: Metadate ER: Food resulted in greater C<sub>max</sub> and AUC compared to fasting.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release solution: Methylin: A high-fat meal delayed peak time (~1 hour), and increased C<sub>max</sub> (~13%) and AUC (~25%).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: Absorption increased when applied to inflamed skin or exposed to heat. Absorption is continuous for 9 hours after application.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: <i>d</i>-methylphenidate: 2.65 &plusmn; 1.11 L/kg, <i>l</i>-methylphenidate: 1.80 &plusmn; 0.91 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 10% to 33%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensive metabolism, predominately via de-esterification by carboxylesterase CES1A1 to alpha-phenyl-piperidine acetic acid (PPAA; ritalinic acid) which has little to no pharmacologic activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release chewable tablets and oral solution: Bioequivalent to immediate-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release capsule: Aptensio XR: 102% (relative to immediate release oral product)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release suspension: Quillivant XR: 95% (relative to immediate release oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch (Daytrana): Lower first-pass effect compared to oral administration; thus, much lower doses (on a mg/kg basis) given via the transdermal route may still produce higher AUCs, compared to the oral route</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release chewable tablet: Methylin: Adults: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Controlled-release capsule: Biphentin [Canadian product]: Children: 2.4 hours; Adults: 2.1 hours; Foquest [Canadian product]: Adults: 6.95 &plusmn; 3.25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aptensio XR: Adults: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Metadate CD: Adults: 6.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ritalin LA: Children: ~2.45 hours (range: 1.5 to 4 hours); Adults: ~3.3 hours (range: 3 to 4.2 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release chewable tablets: ~5.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release orally disintegrating tablet: 4 to 4.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release suspension: Quillivant XR: Children &ge;9 years, Adolescents, and Adults: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release tablet: Concerta: Adolescents and Adults: ~3.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release solution: Methylin: Adults: 2.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release tablet: Adults: 2.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: Children and Adolescents 6 to 17 years: <i>d</i>-methylphenidate ~4 to 5 hours, <i>l</i>-methylphenidate 1.4 to 2.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release chewable tablet: Methylin: ~1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release chewable tablet: QuilliChew ER: 5 hours (median)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Controlled-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Biphentin [Canadian product]: Children: Initial: ~2.5 hours; Adults: Initial: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foquest [Canadian product]: Adults: Initial peak at ~1.6 hours followed by second peak at ~12.5 hours (range: 11 to 16 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aptensio XR: Adults: Initial: ~2 hours; Second peak: ~8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Metadate CD: Children: Initial: ~1.5 hours; Second peak: ~4.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ritalin LA:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: Initial: 1 to 3 hours; Second peak: 5 to 11 hour</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: Initial: 1.3 to 4 hours; Second peak: 4.3 to 6.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release orally disintegrating tablet: Cotempla XR-ODT: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release suspension: Quillivant XR: Children (9 to 12 years): 4.05 hours (range: 3.98 to 6 hours); Adolescents (13 to 15 years): 2 hours (range: 1.98 to 4 hours); Adults: 4 hours (range: 1.3 to 7.3 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release tablet: Concerta: Initial: ~1 hours, followed by gradually ascending concentrations over 5 to 9 hours; Mean peak: 6 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release solution: Methylin: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release tablet: Children: 1.9 hours (range: 0.3 to 4.4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sustained-release tablet: Children: 4.7 hours (range: 1.3 to 8.2 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: ~8 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (90% as metabolites and unchanged drug); Feces (1% to 3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45303307\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release capsule: Ritalin LA: Time until the between peak minimum and the time until the second peak were delayed and more variable in children 10 to 12 years of age compared to adults. After a 20 mg dose, concentrations in children were approximately twice the concentrations observed in 18 to 35 year old adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\"> Extended release suspension: Quillivant XR: After a single oral dose of 60 mg plasma concentrations of methylphenidate in children (9 to 12 years old) were approximately twice the concentrations observed in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal: The C<sub>max</sub> and AUC of <i>d</i>-methylphenidate were ~50% lower in adolescents, compared to children, following either a 1-day or 7-day administration of 10 mg/9 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053979\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Methylphenidate is a racemic mixture of d- and l-enantiomers; the d-enantiomer is more active than the l-enantiomer. Treatment with methylphenidate should include &ldquo;drug holidays&rdquo; or periodic discontinuation in order to assess the patient's requirements, decrease tolerance and limit suppression of linear growth and weight. Medications used to treat ADHD should be part of a total treatment program that may include other components such as psychological, educational, and social measures. Concerta&reg;, Metadate CD&reg;, and Ritalin LA&reg; are formulated to deliver methylphenidate in a biphasic release profile; Concerta&reg; is an osmotic controlled release formulation, with an immediate release (within 1 hour) outer coating; once daily Concerta&reg; has been shown to be as effective as immediate release methylphenidate tablets administered 3 times/day (Pelham, 2001). Metadate CD&reg; capsules contain both immediate release beads (30% of the dose) and extended release beads (70% of the dose). Ritalin LA&reg; capsules contain both immediate release beads (50% of the dose) and enteric coated, delayed release beads (50% of the dose). Methylin&reg; and Ritalin-SR&reg; tablets are color and additive free; Methylin&reg; oral solution is colorless. Concerta&reg; tablets may be seen on abdominal x-ray under certain conditions (eg, when digital enhancing techniques are used). Quillivant&trade; XR powder for oral suspension contains a combination of uncoated and coated ion exchange resin complex and a buffering solution based on the Oral XR + platform (Wigal, 2013). Once reconstituted with water forms an extended release suspension that contains approximately 20% immediate release and 80% extended release methylphenidate. </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Daytrana&trade; Transdermal System consists of an adhesive-based matrix containing active drug which is dispersed in acrylic adhesive that is dispersed in a silicone adhesive. The patch consists of 3 layers: A polyester/ethylene vinyl acetate laminate (outside) film backing, the adhesive layer containing methylphenidate, and a flouropolymer-coated polyester protective liner (which must be removed before application). Long-term use of the transdermal system or Concerta&reg; &gt;7 weeks, Metadate&reg; CD &gt;3 weeks,  and Ritalin LA&reg; &gt;2 weeks have not been adequately studied; long-term usefulness should be periodically re-evaluated for the individual patient. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989423\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Aptensio XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Methylphenidate HCl ER (LA) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $1,027.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $567.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $580.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $596.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (30): $371.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Ritalin LA Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $1,194.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $1,194.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,221.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $1,255.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Methylphenidate HCl ER (CD) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $560.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $560.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $560.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $768.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $944.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $944.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Methylphenidate HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $315.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $450.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $642.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Daytrana Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/9 hrs (30): $399.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/9 hrs (30): $399.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/9 hrs (30): $399.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/9 hrs (30): $399.77</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Methylin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (500 mL): $84.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (500 mL): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Methylphenidate HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (500 mL): $451.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (500 mL): $643.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Quillivant XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (120 mL): $328.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Chewable Extended Release</b> (QuilliChew ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $1,286.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,286.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $1,286.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Extended Release Dispersible</b> (Cotempla XR-ODT Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.6 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">17.3 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25.9 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Methylphenidate HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg (100): $622.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">27 mg (100): $637.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">36 mg (100): $657.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">54 mg (100): $715.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Concerta Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg (100): $1,306.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">27 mg (100): $1,339.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">36 mg (100): $1,381.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">54 mg (100): $1,503.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Metadate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $216.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Methylphenidate HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $750.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg (100): $973.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $775.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">27 mg (100): $997.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">36 mg (100): $1,028.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">54 mg (100): $1,119.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">72 mg (100): $2,280.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Methylphenidate HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $73.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $105.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $151.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ritalin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $78.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $112.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $161.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195283\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adaphen (ZA);</li>\n      <li>Adaphen XL (ZA);</li>\n      <li>Addwize (IN);</li>\n      <li>Aradix Retard (CL, PE, PY);</li>\n      <li>Artige (AU);</li>\n      <li>Attenta (AU);</li>\n      <li>Aurium (PY);</li>\n      <li>Cognil (PY);</li>\n      <li>Comcerta (VE);</li>\n      <li>Concentra (BD);</li>\n      <li>Concentra SR (BD);</li>\n      <li>Concerta (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CY, DE, DK, DO, EC, EE, ES, FI, GR, GT, GY, HK, HN, HR, ID, IE, IL, IS, JM, JP, KW, LB, LT, LU, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, QA, RO, SA, SE, SG, SI, SK, SR, SV, TH, TR, TT, TW, UY, VN, ZW);</li>\n      <li>Concerta LP (FR);</li>\n      <li>Concerta Oros (KR);</li>\n      <li>Concerta XL (GB);</li>\n      <li>Equasym (BE, CH, ES, IE);</li>\n      <li>Equasym Depot (DK, NO, SE);</li>\n      <li>Equasym Retard (DE);</li>\n      <li>Equasym XL (GB);</li>\n      <li>Inspiral (IN);</li>\n      <li>Kontserta (UA);</li>\n      <li>Matoride XL (GB);</li>\n      <li>Medikinet (BE, CH, DE, DK, EE, GB, IE, NO, PL, SE);</li>\n      <li>Medikinet CR (DE);</li>\n      <li>Medikinet MR (IL, SG);</li>\n      <li>Medikinet Retard (KR);</li>\n      <li>Medikinet XL (EE, GB);</li>\n      <li>Metadate CD SR (KR);</li>\n      <li>Methylin (AR);</li>\n      <li>Methylphen (BD);</li>\n      <li>Metidate (IE);</li>\n      <li>MFD (AR);</li>\n      <li>Nebapul (CL);</li>\n      <li>Penid (KR);</li>\n      <li>Phenida (PK);</li>\n      <li>Prohiper (ID);</li>\n      <li>Quasym LP (FR);</li>\n      <li>Rilatine (LU);</li>\n      <li>Ritalin (AE, AT, AU, BB, BF, BH, BJ, CH, CI, CL, CO, CY, CZ, DE, DK, EG, ET, GB, GH, GM, GN, HK, ID, IE, IL, IQ, IR, IS, JO, JP, KE, KW, LB, LK, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NO, NZ, OM, PE, PK, QA, SA, SC, SD, SE, SG, SI, SL, SN, SY, TN, TW, TZ, UG, VE, YE, ZM, ZW);</li>\n      <li>Ritalin LA (AU, BB, CO, HK, ID, IL, MY, PE, PT, TR);</li>\n      <li>Ritalin LP (VE);</li>\n      <li>Ritalin SR (NO, VE);</li>\n      <li>Ritalin-SR (CH, HK, ID, MY, NZ, SG);</li>\n      <li>Ritalina (AR, BR, PY, UY);</li>\n      <li>Ritalina LA (BR, UY);</li>\n      <li>Ritaline (BE, FR, GR);</li>\n      <li>Ritaline LP (FR);</li>\n      <li>Rubifen (AR, ES, LK, MY, NZ, PT, SG, TH, UY);</li>\n      <li>Rubifen SR (NZ);</li>\n      <li>Tradea (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tradea LP (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Xenidate XL (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, &quot;ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,&quot; <i>Pediatrics</i>, 2011, 128(5):1007-22.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: http://americanheart.mediaroon.com/index.php?s=43&amp;item=422.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder, &ldquo;Clinical Practice Guideline: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder,&rdquo; <i>Pediatrics</i>, 2001, 108(4):1033-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/11581465/pubmed\" target=\"_blank\" id=\"11581465\">11581465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arnold LE, Lindsay RL, L&oacute;pez FA, et al, &quot;Treating Attention-Deficit/Hyperactivity Disorder With a Stimulant Transdermal Patch: The Clinical Art,&quot; <i>Pediatrics</i>, 2007, 120(5):1100-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/17974748/pubmed\" target=\"_blank\" id=\"17974748\">17974748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bolea-Alamanac BM, Green A, Verma G, et al, &quot;Methylphenidate Use in Pregnancy and Lactation, a Systematic Review of Evidence,&quot; <i>Br J Clin Pharmacol</i>, 2013, doi: 10.1111/bcp.12138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/23593966/pubmed\" target=\"_blank\" id=\"23593966\">23593966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper WO, Habel LA, Sox CM, et al, &quot;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&quot; <i>N Engl J Med</i>, 2011, 365(20):1896-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/22043968/pubmed\" target=\"_blank\" id=\"22043968\">22043968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dideriksen D, Potteg&aring;rd A, Hallas J, et al, &quot;First Trimester <i>in utero</i> Exposure to Methylphenidate,&quot; <i>Basic Clin Pharmacol Toxicol</i>, 2013, 112(2):73-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/23136875/pubmed\" target=\"_blank\" id=\"23136875\">23136875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghuman JK, Arnold LE, and Anthony BJ, &quot;Psychopharmacological and Other Treatments in Preschool Children With Attention-Deficit/Hyperactivity Disorder: Current Evidence and Practice,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2008, 18(5):413-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/18844482/pubmed\" target=\"_blank\" id=\"18844482\">18844482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould MS, Walsh BT, Munfakh JL, et al, &quot;Sudden Death and Use of Stimulant Medications in Youths,&quot; <i>Am J Psychiatry</i>, 2009, 166(9):992-1001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/19528194/pubmed\" target=\"_blank\" id=\"19528194\">19528194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenhill L, Kollins S, Abikoff H, et al, &quot;Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers With ADHD,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2006, 45(11):1284-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/17023869/pubmed\" target=\"_blank\" id=\"17023869\">17023869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenhill LL, &ldquo;Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder,&rdquo; <i>Psychiatr Clin North Am</i>, 1992, 15(1):1-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/1347936/pubmed\" target=\"_blank\" id=\"1347936\">1347936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenhill LL, Pliszka S, Dulcan MK, et al, &ldquo;Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 2002, 41(2 Suppl):26S-49S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/11833633/pubmed\" target=\"_blank\" id=\"11833633\">11833633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hackett LP, Kristensen JH, Hale TW, et al, &quot;Methylphenidate and Breast-Feeding,&quot; <i>Ann Pharmacother</i>, 2006, 40(10):1890-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/16940409/pubmed\" target=\"_blank\" id=\"16940409\">16940409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. <i>Pediatrics</i>. 2014;134(4):e935-944.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/25180281 /pubmed\" target=\"_blank\" id=\"25180281 \">25180281 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howard JT, Walick KS, Rivera JC. Preliminary evidence of an association between ADHD medications and diminished bone health in children and adolescents.<i> J Pediatr Orthop</i>. 2015 Sep 20. [Epub ahead of print]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/26398435 /pubmed\" target=\"_blank\" id=\"26398435 \">26398435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly DP and Aylward GP, &ldquo;Attention Deficits in School-Aged Children and Adolescents,&rdquo; <i>Pediatr Clin North Am</i>, 1992, 39(3):487-512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/ 1574355 /pubmed\" target=\"_blank\" id=\" 1574355 \"> 1574355 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maurovich-Horvat E, Kemlink D, H&ouml;gl B, et al, &quot;Narcolepsy and Pregnancy: A Retrospective European Evaluation of 249 Pregnancies,&quot; <i>J Sleep Res</i>, 2013, doi: 10.1111/jsr.12047.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/23560595/pubmed\" target=\"_blank\" id=\"23560595\">23560595</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pelham WE, Gnagy EM, Burrows-Maclean L, et al, &ldquo;Once-a-Day Concerta Methylphenidate Versus Three-Times-Daily Methylphenidate in Laboratory and Natural Settings,&rdquo; <i>Pediatrics</i>, 2001, 107(6), http://www.pediatrics.org/cgi/content/full/107/6/e105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/11389303 /pubmed\" target=\"_blank\" id=\"11389303 \">11389303 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pentikis HS, Simmons RD, Benedict MF, et al, &ldquo;Methylphenidate Bioavailability in Adults When an Extended-Release Multiparticulate Formulation is Administered Sprinkled on Food or as an Intact Capsule,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 2002, 41(4):443-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/11931601/pubmed\" target=\"_blank\" id=\"11931601\">11931601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. <i>Int Clin Psychopharmacol</i>. 2016;31(2):93-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/26544899 /pubmed\" target=\"_blank\" id=\"26544899 \">26544899 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spigset O, Brede WR, and Zahlsen K, &quot;Excretion of Methylphenidate in Breast Milk,&quot; <i>Am J Psychiatry</i>, 2007, 164(2):348.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/17267805/pubmed\" target=\"_blank\" id=\"17267805\">17267805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thorpy M, Zhao CG, and Dauvilliers Y, &quot;Management of Narcolepsy During Pregnancy,&quot; <i>Sleep Med</i>, 2013, 14(4):367-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/23433999/pubmed\" target=\"_blank\" id=\"23433999\">23433999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson C, et al, &quot;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&quot; <i>Circulation</i>, 2008, 117(18):2407-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wigal SB, Childress AC, Belden HW, et al, &quot;NWP06, an Extended Release Oral Suspension of Methylphenidate, Improved Attention-Deficit/Hyperactivity Disorder Symptoms Compared With Placebo in a Laboratory Classroom Study,&quot; <i>J Child Adolesc Psychopharmacol</i>, January 5, 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/23289899/pubmed\" target=\"_blank\" id=\"23289899\">23289899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wigal T, Greenhill L, Chuang S, et al, &quot;Safety and Tolerability of Methylphenidate in Preschool Children With ADHD,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2006, 45(11):1294-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/17028508/pubmed\" target=\"_blank\" id=\"17028508\">17028508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilens TE and Biederman J, &ldquo;The Stimulants,&rdquo; <i>Psychiatr Clin North Am</i>, 1992, 15(1):191-222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-pediatric-drug-information/abstract-text/1347939/pubmed\" target=\"_blank\" id=\"1347939\">1347939</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12600 Version 234.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709144\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F195295\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F195296\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053970\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053963\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F195272\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F195256\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50474161\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F195330\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874704\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053974\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F195291\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053973\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F195336\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F195334\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F195278\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F195260\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26017179\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F195323\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F195265\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F195292\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F195267\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F195281\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053969\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F195259\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F195277\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F45303307\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1053979\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989423\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F195283\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12600|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methylphenidate-drug-information\" class=\"drug drug_general\">Methylphenidate: Drug information</a></li><li><a href=\"topic.htm?path=methylphenidate-patient-drug-information\" class=\"drug drug_patient\">Methylphenidate: Patient drug information</a></li></ul></div></div>","javascript":null}